Sina Marie Hopff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sina Marie Hopff has a total of 261 co-authors. Here are the top co-authors by number of shared publications:
J. Janne Vehreschild
Faculty of Medicine, Institute for Digital Medicine and Clinical Data Science, Goethe University Frankfurt, Frankfurt, Germany
6 shared publicationsSebastian M. Wingen-Heimann
Institute of Translational Research, Cologne Excellence Cluster On Cellular Stress Responses in Aging-Associated Diseases (CECAD), University Hospital Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany
5 shared publications- Jörg Janne Vehreschild
Department II of Internal Medicine, Infectious Diseases, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany
4 shared publications - Katharina S. Appel
Institute for Digital Medicine and Clinical Data Sciences, Faculty of Medicine, Goethe University Frankfurt, 60528 Frankfurt am Main, Germany
4 shared publications - Ramsia Geisler
Goethe University Frankfurt, Faculty of Medicine, Institute for Digital Medicine and Clinical Data Sciences, Germany; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Cologne, Germany
4 shared publications Albrecht Berkessel
Department of Chemistry, University of Cologne, Cologne, Germany
3 shared publications
Latest Publications
- Open Access
- 4 May 2026
- Published by Springer Nature in Infection
- Vol. 54 (4) , 1861-1873
Prognosis and aetiology of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) in patients with active lung or lower head and neck cancer (PEPP-C): a retrospective, matched multicentre cohort study in Germany and Spain
Summary: Purpose: Patients with active lung or lower head and neck cancer (HNC) are at increased risk of infection, particularly hospital-acquired pneumonia (HAP), ventilated HAP (vHAP) and ventilator-associated pneumonia (VAP), due to immunosuppression and treatment-related side effects. These infections are associated with increased mortality, prolonged hospital stays and interruptions in cancer therapy. Despite their clinical relevance, data on epidemiology, risk factors, treatment, and outcomes in this population remain limited. Methods: We conducted a retrospective, observational, multicentre matched cohort study at eight tertiary care centres in Germany and Spain. Patients with lung or lower HNC who received anti-cancer treatment between January 2018 and May 2022 and were hospitalised for at least 48 h were included. Patients with HAP/vHAP/VAP (case group) were matched 1:1 to those without pneumonia (control group) and followed for 90 days. Results: A total of 256 patients were included, with median ages of 65 (cases) and 64 years (controls). Most patients had lung cancer (94%, n = 240), predominantly in stages III-IV (81%, n = 207). In the case group, patients had mostly HAP (88%, n = 113), diagnosed in median 7 days after hospital admission. Common antibiotics given included penicillin derivatives with β-lactamase inhibitors, cephalosporins and carbapenems. Patients with HAP/vHAP/VAP had significantly higher mortality and longer hospital stays ( p < 0.001). Cox regression identified HAP/vHAP/VAP and dysphagia as independent predictors of mortality. Conclusion: HAP/vHAP/VAP imposes a significant clinical burden in patients with lung or lower HNC. Early prevention, timely diagnosis, and close monitoring of high-risk patients are essential to improve outcomes.
- 4 May 2026
- Published by Springer Nature in Infection
- Vol. 54 (4) , 1861-1873
Open AccessPrognosis and aetiology of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) in patients with active lung or lower head and neck cancer (PEPP-C): a retrospective, matched multicentre cohort study in Germany and Spain
Summary: Purpose: Patients with active lung or lower head and neck cancer (HNC) are at increased risk of infection, particularly hospital-acquired pneumonia (HAP), ventilated HAP (vHAP) and ventilator-associated pneumonia (VAP), due to immunosuppression and treatment-related side effects. These infections are associated with increased mortality, prolonged hospital stays and interruptions in cancer therapy. Despite their clinical relevance, data on epidemiology, risk factors, treatment, and outcomes in this population remain limited. Methods: We conducted a retrospective, observational, multicentre matched cohort study at eight tertiary care centres in Germany and Spain. Patients with lung or lower HNC who received anti-cancer treatment between January 2018 and May 2022 and were hospitalised for at least 48 h were included. Patients with HAP/vHAP/VAP (case group) were matched 1:1 to those without pneumonia (control group) and followed for 90 days. Results: A total of 256 patients were included, with median ages of 65 (cases) and 64 years (controls). Most patients had lung cancer (94%, n = 240), predominantly in stages III-IV (81%, n = 207). In the case group, patients had mostly HAP (88%, n = 113), diagnosed in median 7 days after hospital admission. Common antibiotics given included penicillin derivatives with β-lactamase inhibitors, cephalosporins and carbapenems. Patients with HAP/vHAP/VAP had significantly higher mortality and longer hospital stays ( p < 0.001). Cox regression identified HAP/vHAP/VAP and dysphagia as independent predictors of mortality. Conclusion: HAP/vHAP/VAP imposes a significant clinical burden in patients with lung or lower HNC. Early prevention, timely diagnosis, and close monitoring of high-risk patients are essential to improve outcomes.
- Open Access
Patterns of Radiation Therapy During the COVID-19 Pandemic: Results from the Multicenter, Cross-Sectoral Registry of the German National Pandemic Cohort Network (NAPKON)
Background: Cancer patients receiving or having received radiotherapy (RT) represent a clinically vulnerable group during the COVID-19 pandemic. However, systematic data on their clinical course, comorbidities, and vaccination status are limited. The German National Pandemic Cohort Network (NAPKON), established to systematically collect comprehensive clinical data on COVID-19 patients nationwide, provides a unique opportunity to address this gap. This study aimed to describe radiation therapy patterns and COVID-19-related clinical characteristics among patients documented within the NAPKON Cross-Sectoral Platform (SUEP). Methods: This multicenter, descriptive analysis was conducted within the framework of the German National Pandemic Cohort Network (NAPKON). All patients with documented RT and confirmed SARS-CoV-2 infection were identified in the SUEP database. RT was classified relative to the documented infection date as occurring before, during, or after infection. Demographic, clinical, laboratory, imaging, and vaccination data were extracted and analyzed descriptively. Due to the small sample size, no correlation or multivariable analyses were performed. Results: A total of n = 90 patients were included in the analysis. The median age was 65 years (range 22–90), and 56% were male. Most patients (93%) received one course of RT, most frequently targeting specific organ systems (54%), while total body irradiation was performed in 4%. The median radiation dose was 45 Gy (IQR 30–60). Among 68 patients with evaluable timing information, RT had been administered before infection in 53 patients (77.9%), during infection in 3 patients (4.4%), and after infection in 12 patients (17.6%). At the time of SARS-CoV-2 detection, 76% of patients experienced a phase without complications, 19% a phase with complications, and 2% a critical phase. The majority of vaccinated individuals had received Comirnaty (BioNTech/Pfizer; 80%). COVID-19-typical findings were identified in 18% of chest X-rays and 27% of CT scans. Clinical and laboratory characteristics showed no substantial differences by hospital length of stay. Conclusions: Patients with documented RT and SARS-CoV-2 infection in the NAPKON registry predominantly experienced mild or moderate COVID-19 courses and showed a relatively high vaccination uptake. However, due to the descriptive study design and the absence of a control group, these findings should not be interpreted as being attributable to RT itself but rather as a characterization of this registry cohort. Importantly, the cohort mainly comprised patients with a history of RT before SARS-CoV-2 infection, whereas only a small minority received RT during infection. Although the analysis was descriptive and limited by missing data, it demonstrates the feasibility and scientific value of integrating oncologic subcohorts within national pandemic research networks. Continued longitudinal analyses will be essential to further characterize outcomes of patients with cancer and RT in future pandemics.
Open AccessPatterns of Radiation Therapy During the COVID-19 Pandemic: Results from the Multicenter, Cross-Sectoral Registry of the German National Pandemic Cohort Network (NAPKON)
Background: Cancer patients receiving or having received radiotherapy (RT) represent a clinically vulnerable group during the COVID-19 pandemic. However, systematic data on their clinical course, comorbidities, and vaccination status are limited. The German National Pandemic Cohort Network (NAPKON), established to systematically collect comprehensive clinical data on COVID-19 patients nationwide, provides a unique opportunity to address this gap. This study aimed to describe radiation therapy patterns and COVID-19-related clinical characteristics among patients documented within the NAPKON Cross-Sectoral Platform (SUEP). Methods: This multicenter, descriptive analysis was conducted within the framework of the German National Pandemic Cohort Network (NAPKON). All patients with documented RT and confirmed SARS-CoV-2 infection were identified in the SUEP database. RT was classified relative to the documented infection date as occurring before, during, or after infection. Demographic, clinical, laboratory, imaging, and vaccination data were extracted and analyzed descriptively. Due to the small sample size, no correlation or multivariable analyses were performed. Results: A total of n = 90 patients were included in the analysis. The median age was 65 years (range 22–90), and 56% were male. Most patients (93%) received one course of RT, most frequently targeting specific organ systems (54%), while total body irradiation was performed in 4%. The median radiation dose was 45 Gy (IQR 30–60). Among 68 patients with evaluable timing information, RT had been administered before infection in 53 patients (77.9%), during infection in 3 patients (4.4%), and after infection in 12 patients (17.6%). At the time of SARS-CoV-2 detection, 76% of patients experienced a phase without complications, 19% a phase with complications, and 2% a critical phase. The majority of vaccinated individuals had received Comirnaty (BioNTech/Pfizer; 80%). COVID-19-typical findings were identified in 18% of chest X-rays and 27% of CT scans. Clinical and laboratory characteristics showed no substantial differences by hospital length of stay. Conclusions: Patients with documented RT and SARS-CoV-2 infection in the NAPKON registry predominantly experienced mild or moderate COVID-19 courses and showed a relatively high vaccination uptake. However, due to the descriptive study design and the absence of a control group, these findings should not be interpreted as being attributable to RT itself but rather as a characterization of this registry cohort. Importantly, the cohort mainly comprised patients with a history of RT before SARS-CoV-2 infection, whereas only a small minority received RT during infection. Although the analysis was descriptive and limited by missing data, it demonstrates the feasibility and scientific value of integrating oncologic subcohorts within national pandemic research networks. Continued longitudinal analyses will be essential to further characterize outcomes of patients with cancer and RT in future pandemics.
- Open Access
- 16 February 2026
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 27 (7) , 1-10
Healthcare resource utilization and costs of letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation in a real-world, multi-centre study in Germany
Objectives: Letermovir has demonstrated efficacy and tolerability as prophylaxis against clinically significant cytomegalovirus infection (csCMVi) in CMV-seropositive adult patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) compared to alternative antivirals. Despite these advantages, associated costs remain substantial. This study addresses the evidence gap by evaluating the health economic impact of CMV prophylaxis with letermovir in a real-world setting for alloHCT patients. Methods: This retrospective, multi-centre case-control study was conducted at six German tertiary care centres. A micro-costing approach evaluated hospitalisation and anti-CMV drug acquisition costs over a 48-week follow-up period post-alloHCT. The analysis included patients surviving at least 100 days following alloHCT, comparing individuals receiving letermovir prophylaxis (cases) with those who did not (controls) between January 2018 and April 2021. Results: The incidence of csCMVi was significantly higher in the control than in the letermovir group (56%, n = 98 vs. 34%, n = 63, p < 0.001). Median hospital length of stay was significantly longer in the control group (45 days, IQR 36–66) compared to the letermovir group (39 days, IQR 32–55; p < 0.001). Hospitalisation costs were comparable ( p = 0.865), while anti-CMV drug acquisition and overall direct treatment costs were significantly higher in the letermovir group (€21,844, 95% CI 19,247 − 25,107 vs. €7,711, 95% CI 12,692 − 25,107, p < 0.001; 81,871, 95% CI 76,721 − 87,021 vs. 67,161, 95% CI 61,693 − 72,629, p < 0.001). Besides letermovir, cost drivers post-alloHCT were rehospitalisation and csCMVi. Conclusions: Our study demonstrated higher anti-CMV drug acquisition costs and overall direct treatment costs in patients receiving letermovir prophylaxis compared to controls. However, these higher costs are accompanied by significantly improved clinical outcomes.
- 16 February 2026
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 27 (7) , 1-10
Open AccessHealthcare resource utilization and costs of letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation in a real-world, multi-centre study in Germany
Objectives: Letermovir has demonstrated efficacy and tolerability as prophylaxis against clinically significant cytomegalovirus infection (csCMVi) in CMV-seropositive adult patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) compared to alternative antivirals. Despite these advantages, associated costs remain substantial. This study addresses the evidence gap by evaluating the health economic impact of CMV prophylaxis with letermovir in a real-world setting for alloHCT patients. Methods: This retrospective, multi-centre case-control study was conducted at six German tertiary care centres. A micro-costing approach evaluated hospitalisation and anti-CMV drug acquisition costs over a 48-week follow-up period post-alloHCT. The analysis included patients surviving at least 100 days following alloHCT, comparing individuals receiving letermovir prophylaxis (cases) with those who did not (controls) between January 2018 and April 2021. Results: The incidence of csCMVi was significantly higher in the control than in the letermovir group (56%, n = 98 vs. 34%, n = 63, p < 0.001). Median hospital length of stay was significantly longer in the control group (45 days, IQR 36–66) compared to the letermovir group (39 days, IQR 32–55; p < 0.001). Hospitalisation costs were comparable ( p = 0.865), while anti-CMV drug acquisition and overall direct treatment costs were significantly higher in the letermovir group (€21,844, 95% CI 19,247 − 25,107 vs. €7,711, 95% CI 12,692 − 25,107, p < 0.001; 81,871, 95% CI 76,721 − 87,021 vs. 67,161, 95% CI 61,693 − 72,629, p < 0.001). Besides letermovir, cost drivers post-alloHCT were rehospitalisation and csCMVi. Conclusions: Our study demonstrated higher anti-CMV drug acquisition costs and overall direct treatment costs in patients receiving letermovir prophylaxis compared to controls. However, these higher costs are accompanied by significantly improved clinical outcomes.
- Open Access
- 29 January 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Clinical and Pharmacoeconomic evaluation of Fidaxomicin in patients over 65 years of age and immunocompromised patients with recurrent and refractory Clostridioides difficile infection
Background: Recurrent or refractory Clostridioides difficile infection (CDI) often affects older and immunocompromised patients, posing clinical and economic challenges. While fidaxomicin has shown lower recurrence rates than vancomycin in the general population, evidence in this population remains limited. Methods: This retrospective, multicentre case-control study compared patients aged > 65 years or immunocompromised patients receiving fidaxomicin (case group) with those treated with vancomycin (control group) for recurrent or refractory CDI. A microcosting approach was used to assess direct treatment costs. Results: A total of 344 patients were included (172 per group). Compared to the control group, the fidaxomicin group presented a significantly higher rate of symptom reduction on day 10 ( n = 163, 95% vs. n = 147, 86%; p = 0.004) and lower CDI recurrence rates ( n = 36, 21% vs. n = 63, 37%; p = 0.001). While the mean CDI treatment costs per patient were significantly higher in the fidaxomicin group ( p < 0.001), the hospitalisation and overall treatment costs were comparable (€19,898, 95% CI €16,151-€23,645 vs. €20,469, 95% CI €16,837-€24,101, p = 0.811; €17,798, 95% CI €14,620-€20,975 vs. €17,300, 95% CI €14,199-€20,400, p = 0.840). Key cost drivers were hospitalisation, intensive care unit treatment, and severe initial CDI. Conclusions: Despite higher drug acquisition costs of fidaxomicin, overall treatment costs were comparable between the two groups with better clinical outcomes in patients treated with fidaxomicin. Clinical trial number: Not applicable.
- 29 January 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Open AccessClinical and Pharmacoeconomic evaluation of Fidaxomicin in patients over 65 years of age and immunocompromised patients with recurrent and refractory Clostridioides difficile infection
Background: Recurrent or refractory Clostridioides difficile infection (CDI) often affects older and immunocompromised patients, posing clinical and economic challenges. While fidaxomicin has shown lower recurrence rates than vancomycin in the general population, evidence in this population remains limited. Methods: This retrospective, multicentre case-control study compared patients aged > 65 years or immunocompromised patients receiving fidaxomicin (case group) with those treated with vancomycin (control group) for recurrent or refractory CDI. A microcosting approach was used to assess direct treatment costs. Results: A total of 344 patients were included (172 per group). Compared to the control group, the fidaxomicin group presented a significantly higher rate of symptom reduction on day 10 ( n = 163, 95% vs. n = 147, 86%; p = 0.004) and lower CDI recurrence rates ( n = 36, 21% vs. n = 63, 37%; p = 0.001). While the mean CDI treatment costs per patient were significantly higher in the fidaxomicin group ( p < 0.001), the hospitalisation and overall treatment costs were comparable (€19,898, 95% CI €16,151-€23,645 vs. €20,469, 95% CI €16,837-€24,101, p = 0.811; €17,798, 95% CI €14,620-€20,975 vs. €17,300, 95% CI €14,199-€20,400, p = 0.840). Key cost drivers were hospitalisation, intensive care unit treatment, and severe initial CDI. Conclusions: Despite higher drug acquisition costs of fidaxomicin, overall treatment costs were comparable between the two groups with better clinical outcomes in patients treated with fidaxomicin. Clinical trial number: Not applicable.
- Open Access
- 31 October 2025
- Published by Springer Nature in Infection
- Vol. 54 (1) , 377-387
Clinical and health economic impact of isavuconazole for treatment of invasive aspergillosis and mucormycosis: a retrospective, matched multicentre cohort study in Germany
Summary: Purpose: Isavuconazole is effective against invasive aspergillosis (IA) and mucormycosis (IM) and may improve clinical outcomes compared to alternative antifungal treatments. However, real-world evidence regarding its clinical use and the health economic burden of inpatient treatment for IA and IM of patients with haematological malignancies remains limited. Methods: A retrospective, matched, multicentre cohort study was conducted in six German tertiary care centres. The study included adults with haematological or oncological diseases who were diagnosed with proven, probable, or possible IA or IM. We compared clinical and health economic outcomes under first-line treatment initiated with isavuconazole (case group) vs. liposomal amphotericin B (L-AmB) and/or voriconazole (control group) between 2016 and 2021. A micro-costing approach was used to assess direct treatment costs. Results: We included 198 patients (99 per group), most with a probable or possible classification. Median length of hospital stay was 44 days (interquartile range [IQR] 27–74) in the isavuconazole group and 39 days (IQR 26–56) in the control group ( p = 0.285). All-cause mortality rates were 29% and 31% ( p = 0.530), with fungal-related deaths occurring in 21% ( n = 6) and 23% ( n = 7, p = 0.862), respectively. Mean antifungal drug acquisition and overall treatment costs were significantly higher in the isavuconazole group (€22,389 vs. €12,801, p = 0.003; €49,042 vs. €39,369, p = 0.030, respectively), while mean hospitalisation costs were comparable (€28,570 vs. €31,160, p = 0.406). Conclusion: Our real-world analysis confirmed that first-line treatment initiated with isavuconazole resulted in clinical outcomes equivalent to those of L-AmB and/or voriconazole in patients with IA or IM. However, treatment costs during the in-patient stay were higher with isavuconazole.
- 31 October 2025
- Published by Springer Nature in Infection
- Vol. 54 (1) , 377-387
Open AccessClinical and health economic impact of isavuconazole for treatment of invasive aspergillosis and mucormycosis: a retrospective, matched multicentre cohort study in Germany
Summary: Purpose: Isavuconazole is effective against invasive aspergillosis (IA) and mucormycosis (IM) and may improve clinical outcomes compared to alternative antifungal treatments. However, real-world evidence regarding its clinical use and the health economic burden of inpatient treatment for IA and IM of patients with haematological malignancies remains limited. Methods: A retrospective, matched, multicentre cohort study was conducted in six German tertiary care centres. The study included adults with haematological or oncological diseases who were diagnosed with proven, probable, or possible IA or IM. We compared clinical and health economic outcomes under first-line treatment initiated with isavuconazole (case group) vs. liposomal amphotericin B (L-AmB) and/or voriconazole (control group) between 2016 and 2021. A micro-costing approach was used to assess direct treatment costs. Results: We included 198 patients (99 per group), most with a probable or possible classification. Median length of hospital stay was 44 days (interquartile range [IQR] 27–74) in the isavuconazole group and 39 days (IQR 26–56) in the control group ( p = 0.285). All-cause mortality rates were 29% and 31% ( p = 0.530), with fungal-related deaths occurring in 21% ( n = 6) and 23% ( n = 7, p = 0.862), respectively. Mean antifungal drug acquisition and overall treatment costs were significantly higher in the isavuconazole group (€22,389 vs. €12,801, p = 0.003; €49,042 vs. €39,369, p = 0.030, respectively), while mean hospitalisation costs were comparable (€28,570 vs. €31,160, p = 0.406). Conclusion: Our real-world analysis confirmed that first-line treatment initiated with isavuconazole resulted in clinical outcomes equivalent to those of L-AmB and/or voriconazole in patients with IA or IM. However, treatment costs during the in-patient stay were higher with isavuconazole.
- Open Access
- 13 October 2025
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 19 (1) , 504
Fatal outcome of severe serotonin syndrome and acute respiratory distress syndrome after self-poisoning with paroxetine: a case report
Background: Paroxetine overdose can cause serotonin syndrome, presenting with a constellation of manifestations that range from mild symptoms to life-threatening complications. Current evidence regarding the management of paroxetine-induced serotonin syndrome is limited to case reports and small case series, with no definitive recommendations established from controlled clinical trials in humans. Case presentation: In this case report, we describe an exceptional and severe clinical course of a 26-year-old Caucasian female who ingested multiple drugs with suicidal intention—including 4000 mg paroxetine. The patient developed severe serotonin syndrome complicated by acute respiratory distress syndrome, necessitating invasive mechanical ventilation and veno-venous extracorporeal membrane oxygenation. Serotonin syndrome prevailed unusually long, with serum paroxetine levels remaining within the lethal dose range for 20 days postingestion. Despite intensive therapeutic interventions—including CytoSorb™ hemoadsorption, adjunctive corticosteroids, olanzapine (10 mg/day), and maximal intensive care treatment—the patient died on day 20 postingestion. Conclusion: Our case illustrates the importance of early and aggressive intervention, while highlighting the limited efficacy of currently available extracorporeal elimination techniques in severe paroxetine overdose. Given the protracted and progressive symptoms observed in this case report and others, clinicians should remain vigilant for pharmacokinetic complications such as pharmacobezoars or poor CYP2D6 metabolism in massive selective serotonin reuptake inhibitor overdose, leading to an early and aggressive treatment in similar cases with serotonin syndrome.
- 13 October 2025
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 19 (1) , 504
Open AccessFatal outcome of severe serotonin syndrome and acute respiratory distress syndrome after self-poisoning with paroxetine: a case report
Background: Paroxetine overdose can cause serotonin syndrome, presenting with a constellation of manifestations that range from mild symptoms to life-threatening complications. Current evidence regarding the management of paroxetine-induced serotonin syndrome is limited to case reports and small case series, with no definitive recommendations established from controlled clinical trials in humans. Case presentation: In this case report, we describe an exceptional and severe clinical course of a 26-year-old Caucasian female who ingested multiple drugs with suicidal intention—including 4000 mg paroxetine. The patient developed severe serotonin syndrome complicated by acute respiratory distress syndrome, necessitating invasive mechanical ventilation and veno-venous extracorporeal membrane oxygenation. Serotonin syndrome prevailed unusually long, with serum paroxetine levels remaining within the lethal dose range for 20 days postingestion. Despite intensive therapeutic interventions—including CytoSorb™ hemoadsorption, adjunctive corticosteroids, olanzapine (10 mg/day), and maximal intensive care treatment—the patient died on day 20 postingestion. Conclusion: Our case illustrates the importance of early and aggressive intervention, while highlighting the limited efficacy of currently available extracorporeal elimination techniques in severe paroxetine overdose. Given the protracted and progressive symptoms observed in this case report and others, clinicians should remain vigilant for pharmacokinetic complications such as pharmacobezoars or poor CYP2D6 metabolism in massive selective serotonin reuptake inhibitor overdose, leading to an early and aggressive treatment in similar cases with serotonin syndrome.
- Open Access
- 23 July 2025
- Published by MDPI AG in Infectious Disease Reports
- Vol. 17 (4) , 87
Clostridioides difficile Infection in the United States of America—A Comparative Event Risk Analysis of Patients Treated with Fidaxomicin vs. Vancomycin Across 67 Large Healthcare Providers
Background/Objectives: Clostridioides difficile infection (CDI) is a major cause of infectious diarrhea in the inpatient and community setting. Real-world data outside the strict environment of randomized controlled trials (RCTs) are needed to improve the quality of evidence. The aim of this study was to compare different clinical outcomes of CDI patients treated with fidaxomicin with those treated with vancomycin using a representative patient population in the United States of America (USA). Methods: Comprehensive real-world data were analyzed for this retrospective observational study, provided by the TriNetX database, an international research network with electronic health records from multiple USA healthcare providers. This includes in- and outpatients treated with fidaxomicin (FDX) or vancomycin (VAN) for CDI between 01/2013 and 12/2023. The following cohorts were compared: (i) patients treated with fidaxomicin within 10 days following CDI diagnosis (FDX group) vs. (ii) patients treated with vancomycin within 10 days following CDI diagnosis (VAN group). Outcomes analysis between the two cohorts was performed after propensity score matching and included event risk and Kaplan–Meier survival analyses for the following concomitant diseases/events occurring during an observational period of 12 months following CDI diagnosis: death, sepsis, candidiasis, infections caused by vancomycin-resistant enterococci, inflammatory bowel disease, cardiovascular disease, psychological disease, central line-associated blood stream infection, surgical site infection, and ventilator-associated pneumonia. Results: Following propensity score matching, 2170 patients were included in the FDX group and VAN groups, respectively. The event risk analysis demonstrated improved outcomes of patients treated with FDX compared to VAN in 6 out of the 10 events that were analyzed. The highest risk ratio (RR) and odds ratio (OR) were found for sepsis (RR: 3.409; OR: 3.635), candidiasis (RR: 2.347; OR: 2.431), and death (RR: 1.710; OR: 1.811). The Kaplan–Meier survival analysis showed an overall survival rate until the end of the 12-month observational period of 87.06% in the FDX group and 78.49% in the VAN group (log-rank p < 0.001). Conclusions: Our comparative event risk analysis demonstrated improved outcomes for patients treated with FDX compared to VAN in most of the observed events and underlines the results of previously conducted RCTs, highlighting the beneficial role of FDX compared to VAN. Further big data analyses from other industrialized countries are needed for comparison with our observations.
- 23 July 2025
- Published by MDPI AG in Infectious Disease Reports
- Vol. 17 (4) , 87
Open AccessClostridioides difficile Infection in the United States of America—A Comparative Event Risk Analysis of Patients Treated with Fidaxomicin vs. Vancomycin Across 67 Large Healthcare Providers
Background/Objectives: Clostridioides difficile infection (CDI) is a major cause of infectious diarrhea in the inpatient and community setting. Real-world data outside the strict environment of randomized controlled trials (RCTs) are needed to improve the quality of evidence. The aim of this study was to compare different clinical outcomes of CDI patients treated with fidaxomicin with those treated with vancomycin using a representative patient population in the United States of America (USA). Methods: Comprehensive real-world data were analyzed for this retrospective observational study, provided by the TriNetX database, an international research network with electronic health records from multiple USA healthcare providers. This includes in- and outpatients treated with fidaxomicin (FDX) or vancomycin (VAN) for CDI between 01/2013 and 12/2023. The following cohorts were compared: (i) patients treated with fidaxomicin within 10 days following CDI diagnosis (FDX group) vs. (ii) patients treated with vancomycin within 10 days following CDI diagnosis (VAN group). Outcomes analysis between the two cohorts was performed after propensity score matching and included event risk and Kaplan–Meier survival analyses for the following concomitant diseases/events occurring during an observational period of 12 months following CDI diagnosis: death, sepsis, candidiasis, infections caused by vancomycin-resistant enterococci, inflammatory bowel disease, cardiovascular disease, psychological disease, central line-associated blood stream infection, surgical site infection, and ventilator-associated pneumonia. Results: Following propensity score matching, 2170 patients were included in the FDX group and VAN groups, respectively. The event risk analysis demonstrated improved outcomes of patients treated with FDX compared to VAN in 6 out of the 10 events that were analyzed. The highest risk ratio (RR) and odds ratio (OR) were found for sepsis (RR: 3.409; OR: 3.635), candidiasis (RR: 2.347; OR: 2.431), and death (RR: 1.710; OR: 1.811). The Kaplan–Meier survival analysis showed an overall survival rate until the end of the 12-month observational period of 87.06% in the FDX group and 78.49% in the VAN group (log-rank p < 0.001). Conclusions: Our comparative event risk analysis demonstrated improved outcomes for patients treated with FDX compared to VAN in most of the observed events and underlines the results of previously conducted RCTs, highlighting the beneficial role of FDX compared to VAN. Further big data analyses from other industrialized countries are needed for comparison with our observations.
- Open Access
- 26 June 2025
- Published by Springer Nature in Infection
- Vol. 53 (6) , 2543-2555
The effect of antibiotic therapy on clinical outcome in patients hospitalized with moderate COVID-19 disease: a prospective multi-center cohort study
Purpose: The benefit of antibiotic treatment (ABT) for patients with moderate COVID-19 is unclear and overtreatment poses the risk of adverse effects such as Clostridioides difficile infection and antibiotic resistance. This multi-center study compares health status improvement between patients with and without ABT at hospital admission. Methods: Between March 2020 and May 2023, hospitalized adults with confirmed SARS-CoV-2 infection were recruited from the German National Pandemic Cohort Network (NAPKON), which includes patients from various hospitals across Germany. The study population included patients with moderate or severe COVID-19 at baseline. The primary objective was to compare health improvement or decline after two weeks between patients who received ABT at baseline and those who did not in the moderate COVID-19 population. The statistical analysis adjusted for confounders such as gender, age, vaccination status, clinical condition, and comorbidities. The severe COVID-19 population was investigated as a secondary objective. Results: A total of 1,317 patients (median age 59 years; 38% women) were eligible for analysis, of whom 1,149 had moderate and 168 severe COVID-19 disease. ABT for pneumonia was administered to 467 patients with moderate and 117 with severe COVID-19. ABT at baseline was significantly associated with a higher deterioration rate after two weeks in patients with moderate COVID-19 (ABT: 292 improvement, 61 deterioration; no ABT: 429 improvement, 14 deterioration). A similar result was obtained in the multiple regression analysis where an odds ratio of 5.00 (95% confidence interval: 2.50 – 10.93) for ABT was observed. Conclusion: We found no benefit of antibiotic therapy in patients with moderate COVID-19. Use of ABT was associated with a higher likelihood of clinical deterioration. Graphical
- 26 June 2025
- Published by Springer Nature in Infection
- Vol. 53 (6) , 2543-2555
Open AccessThe effect of antibiotic therapy on clinical outcome in patients hospitalized with moderate COVID-19 disease: a prospective multi-center cohort study
Purpose: The benefit of antibiotic treatment (ABT) for patients with moderate COVID-19 is unclear and overtreatment poses the risk of adverse effects such as Clostridioides difficile infection and antibiotic resistance. This multi-center study compares health status improvement between patients with and without ABT at hospital admission. Methods: Between March 2020 and May 2023, hospitalized adults with confirmed SARS-CoV-2 infection were recruited from the German National Pandemic Cohort Network (NAPKON), which includes patients from various hospitals across Germany. The study population included patients with moderate or severe COVID-19 at baseline. The primary objective was to compare health improvement or decline after two weeks between patients who received ABT at baseline and those who did not in the moderate COVID-19 population. The statistical analysis adjusted for confounders such as gender, age, vaccination status, clinical condition, and comorbidities. The severe COVID-19 population was investigated as a secondary objective. Results: A total of 1,317 patients (median age 59 years; 38% women) were eligible for analysis, of whom 1,149 had moderate and 168 severe COVID-19 disease. ABT for pneumonia was administered to 467 patients with moderate and 117 with severe COVID-19. ABT at baseline was significantly associated with a higher deterioration rate after two weeks in patients with moderate COVID-19 (ABT: 292 improvement, 61 deterioration; no ABT: 429 improvement, 14 deterioration). A similar result was obtained in the multiple regression analysis where an odds ratio of 5.00 (95% confidence interval: 2.50 – 10.93) for ABT was observed. Conclusion: We found no benefit of antibiotic therapy in patients with moderate COVID-19. Use of ABT was associated with a higher likelihood of clinical deterioration. Graphical
- Open Access
- 1 July 2024
- Published by Elsevier in Journal of Infection
- Vol. 89 (2) , 106220
Real-world experience with letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation: A multi-centre observational study
- 1 July 2024
- Published by Elsevier in Journal of Infection
- Vol. 89 (2) , 106220
Open AccessReal-world experience with letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation: A multi-centre observational study
- Open Access
- 10 June 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26 (1) , e50049
Creation of Standardized Common Data Elements for Diagnostic Tests in Infectious Disease Studies: Semantic and Syntactic Mapping
Background: It is necessary to harmonize and standardize data variables used in case report forms (CRFs) of clinical studies to facilitate the merging and sharing of the collected patient data across several clinical studies. This is particularly true for clinical studies that focus on infectious diseases. Public health may be highly dependent on the findings of such studies. Hence, there is an elevated urgency to generate meaningful, reliable insights, ideally based on a high sample number and quality data. The implementation of core data elements and the incorporation of interoperability standards can facilitate the creation of harmonized clinical data sets. Objective: This study’s objective was to compare, harmonize, and standardize variables focused on diagnostic tests used as part of CRFs in 6 international clinical studies of infectious diseases in order to, ultimately, then make available the panstudy common data elements (CDEs) for ongoing and future studies to foster interoperability and comparability of collected data across trials. Methods: We reviewed and compared the metadata that comprised the CRFs used for data collection in and across all 6 infectious disease studies under consideration in order to identify CDEs. We examined the availability of international semantic standard codes within the Systemized Nomenclature of Medicine - Clinical Terms, the National Cancer Institute Thesaurus, and the Logical Observation Identifiers Names and Codes system for the unambiguous representation of diagnostic testing information that makes up the CDEs. We then proposed 2 data models that incorporate semantic and syntactic standards for the identified CDEs. Results: Of 216 variables that were considered in the scope of the analysis, we identified 11 CDEs to describe diagnostic tests (in particular, serology and sequencing) for infectious diseases: viral lineage/clade; test date, type, performer, and manufacturer; target gene; quantitative and qualitative results; and specimen identifier, type, and collection date. Conclusions: The identification of CDEs for infectious diseases is the first step in facilitating the exchange and possible merging of a subset of data across clinical studies (and with that, large research projects) for possible shared analysis to increase the power of findings. The path to harmonization and standardization of clinical study data in the interest of interoperability can be paved in 2 ways. First, a map to standard terminologies ensures that each data element’s (variable’s) definition is unambiguous and that it has a single, unique interpretation across studies. Second, the exchange of these data is assisted by “wrapping” them in a standard exchange format, such as Fast Health care Interoperability Resources or the Clinical Data Interchange Standards Consortium’s Clinical Data Acquisition Standards Harmonization Model.
- 10 June 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26 (1) , e50049
Open AccessCreation of Standardized Common Data Elements for Diagnostic Tests in Infectious Disease Studies: Semantic and Syntactic Mapping
Background: It is necessary to harmonize and standardize data variables used in case report forms (CRFs) of clinical studies to facilitate the merging and sharing of the collected patient data across several clinical studies. This is particularly true for clinical studies that focus on infectious diseases. Public health may be highly dependent on the findings of such studies. Hence, there is an elevated urgency to generate meaningful, reliable insights, ideally based on a high sample number and quality data. The implementation of core data elements and the incorporation of interoperability standards can facilitate the creation of harmonized clinical data sets. Objective: This study’s objective was to compare, harmonize, and standardize variables focused on diagnostic tests used as part of CRFs in 6 international clinical studies of infectious diseases in order to, ultimately, then make available the panstudy common data elements (CDEs) for ongoing and future studies to foster interoperability and comparability of collected data across trials. Methods: We reviewed and compared the metadata that comprised the CRFs used for data collection in and across all 6 infectious disease studies under consideration in order to identify CDEs. We examined the availability of international semantic standard codes within the Systemized Nomenclature of Medicine - Clinical Terms, the National Cancer Institute Thesaurus, and the Logical Observation Identifiers Names and Codes system for the unambiguous representation of diagnostic testing information that makes up the CDEs. We then proposed 2 data models that incorporate semantic and syntactic standards for the identified CDEs. Results: Of 216 variables that were considered in the scope of the analysis, we identified 11 CDEs to describe diagnostic tests (in particular, serology and sequencing) for infectious diseases: viral lineage/clade; test date, type, performer, and manufacturer; target gene; quantitative and qualitative results; and specimen identifier, type, and collection date. Conclusions: The identification of CDEs for infectious diseases is the first step in facilitating the exchange and possible merging of a subset of data across clinical studies (and with that, large research projects) for possible shared analysis to increase the power of findings. The path to harmonization and standardization of clinical study data in the interest of interoperability can be paved in 2 ways. First, a map to standard terminologies ensures that each data element’s (variable’s) definition is unambiguous and that it has a single, unique interpretation across studies. Second, the exchange of these data is assisted by “wrapping” them in a standard exchange format, such as Fast Health care Interoperability Resources or the Clinical Data Interchange Standards Consortium’s Clinical Data Acquisition Standards Harmonization Model.